Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life” Settings: A Population-Based Study Using a Nationwide Claim Database

Meriem Benmerad, Jules Chassetuillier, Christophe Bouvier, Pierre-Louis Lecoq, Romain Favier, Matthieu Trancart, Sandrine Hayette, Julien Bollard, Audrey Lajoinie, Franck E. Nicolini

Blood (2023) 142 (Supplement 1): 3174.

https://doi.org/10.1182/blood-2023-178703

Published: 2023

Journal Articles

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Franck E. Nicolini, Elisabetta Abruzzese, Gabrielle Roth-Guepin, Rami Abi-Tayeh, Vincent Alcazer, Sandrine Hayette, Stéphane Morisset, Françoise Huguet, Miriam Iezza, Fausto Castagnetti, Delphine Rea

Blood (2023) 142 (Supplement 1): 1799.

https://doi.org/10.1182/blood-2023-178326

Published: 2023

Journal Articles

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Jules Chassetuillier, Meriem Benmerad, Pierre-Louis Lecoq, Romain Favier, Matthieu Trancart, Sandrine Hayette, Vincent Alcazer, Christophe Bouvier, Julien Bollard, Audrey Lajoinie, Franck E. Nicolini

Blood (2023) 142 (Supplement 1): 6369.

https://doi.org/10.1182/blood-2023-179970

Published: 2023

Journal Articles

Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom

Adriana Plesa, Joris Gutrin, Christophe Roumier, Sandrine Hayette, Isabelle Tigaud, Sarah Huet, Delphine Manzoni, Florent Dumezy, Fiorenza Barraco, Herve Ghesquieres, Claude Preudhomme, Pierre Sujobert, Mael Heiblig

Blood (2022) 140 (Supplement 1): 4086–4087.

https://doi.org/10.1182/blood-2022-169959

Published: 2022

Journal Articles

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Franck E. Nicolini, Vincent Alcazer, Pascale Cony-Makhoul, Stéphanie Dulucq, Sandrine Hayette, Stéphane Morisset, Rachel Parat, Christophe Bouvier, Gabriel Etienne

Blood (2022) 140 (Supplement 1): 3918–3919.

https://doi.org/10.1182/blood-2022-163376

Published: 2022

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

Stephanie Dulucq, Frédéric Bauduer, Jean-Michel Cayuela, Patrice Chevallier, Pascale Cony-Makhoul, Yannick Le Bris, Laurence Legros, Herve Maisonneuve, Lydia Roy, Francois-Xavier Mahon, Sandrine Hayette, Delphine Rea, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 2556.

https://doi.org/10.1182/blood-2021-149986

Published: 2021

Journal Articles

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Franck E. Nicolini, Vincent Alcazer, Stephanie Dulucq, Sandrine Hayette, Jean-Michel Cayuela, Stephane Morisset, Christophe Bouvier, Francois-Xavier Mahon, Gabriel Etienne, Delphine Rea

Blood (2021) 138 (Supplement 1): 2552.

https://doi.org/10.1182/blood-2021-146722

Published: 2021

Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2021-147537

Published: 2021

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Franck E Nicolini, MDPhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD, Stephanie Dulucq, PharmD, PhD, Sandrine Hayette, PhD, Stephane Morisset, BioStat, Jean-Michel Cayuela, PharmD, PhD, Marie-Pierre Fort, PhD, Christophe Bouvier, CRA, Clemence Deteix-Santana, MD, Etienne Lengline, MD, Delphine Rea, MDPhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-139921

Published: 2020

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

Adriana Plesa, Christophe Roumier, PharmD, Florent Dumezy, PharmD, Delphine Manzoni, PharmD, Pierre Sujobert, MD PhD, Sandrine Hayette, Isabelle Tigaud, MD, Claude Preudhomme, Karine Celli-Lebras, CRA, Yves Bertrand, MD, Herve Dombret, Xavier Thomas, MD, Meyling Cheok, BSPharm, PhD

Blood (2018) 132 (Supplement 1): 4009.

https://doi.org/10.1182/blood-2018-99-119857

Published: 2018

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

Sarah Huet, Etienne Paubelle, Camille Lours, Beatrice Grange, Lucien Courtois, Kaddour Chabane, Carole Charlot, Isabelle Mosnier, Thomas Simonet, Sandrine Hayette, Isabelle Tigaud, Xavier Thomas, Gilles Salles, Fabien Subtil, Pierre Sujobert

Blood (2018) 132 (8): 865–867.

https://doi.org/10.1182/blood-2018-03-840348

Published: 2018

Includes: Supplemental data

Journal Articles

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

Juliette Lambert, Jérôme Lambert, MDPhD, Xavier Thomas, MD, Alice Marceau-Renaut, PharmD, Aline Renneville, MDPhD, Marie-Magdelaine Coude, MD, Sandrine Hayette, MD, Christian Recher, MD PhD, Emmanuel Raffoux, MD, Arnaud Pigneux, MD PhD, Céline Berthon, MD PhD, Christine Terré, PharmD, PhD, Karine Celli-Lebras, CRA, Sylvie Castaigne, MD, Nicolas Boissel, MD PhD, Philippe Rousselot, Herve Dombret, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 29.

https://doi.org/10.1182/blood.V130.Suppl_1.29.29

Published: 2017

Journal Articles

No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline

Alexis Genthon, Franck Emmanuel Nicolini, MD PhD, Marc G. Berger, MD PhD, Sandrine Saugues, Alexandre Janel, Denis Guyotat, Sandrine Hayette, MD, Lydia Campos, Pascale Flandrin-Gresta, MD

Blood (2017) 130 (Supplement 1): 2907.

https://doi.org/10.1182/blood.V130.Suppl_1.2907.2907

Published: 2017

Journal Articles

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia

Maël Heiblig, Etienne Paubelle, Adriana Plesa, Marie-Oldine Geay, Delphine Manzoni, Sophie Gazzo, Isabelle Tigaud, Evelyne Callet-Bauchu, Sarah Huet, Gilles Salles, Xavier Thomas, Sandrine Hayette, Pierre Sujobert

Blood (2017) 129 (1): 128–131.

https://doi.org/10.1182/blood-2016-09-741355

Published: 2017

Journal Articles

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Philippe Attias, Aline Renneville, MD, Xavier Thomas, MD PhD, Cecile Bally, Sandrine Hayette, Hassan Farhat, MD, Virginie Eclache, MD, Alice Marceau, Bruno Cassinat, PharmD, PhD, Jean Feuillard, MD PhD Pr, Christine Terré, PharmD, PhD, Eric Delabesse, PharmD, PhD, Sophie Park, MD PhD, Julie Lejeune, Sylvie Chevret, MD PhD, Lionel Ades, MD PhD, Claude Preudhomme, MD PhD, Pierre Fenaux, MD PhD

Blood (2016) 128 (22): 2861.

https://doi.org/10.1182/blood.V128.22.2861.2861

Published: 2016

NARROW

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life” Settings: A Population-Based Study Using a Nationwide Claim Database

Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases

The Outcome of Treatment-Free Remission after First-Line Nilotinib or Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients Is Different

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Stemness Signature in AML: GEP with 17 Genes Score Versus Leukemic Stem Cell (LSC) Quantification By Multiparameter Flow Cytometry (MFC)

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Validation of the prognostic value of the knowledge bank approach to determine AML prognosis in real life

Early Detection of WT1 minimal Residual Disease Predicts Outcome in Acute Myeloid Leukemia and Identify Patients with High Risk of Relapse Independently of Allogeneic Stem Cell Transplantation

No Influence of BCR-ABL1 Transcript Types e13a2 and e14a2 on MR4.5 in Patients with Chronic Myeloid Leukemia Treated with Nilotinib Frontline

Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia

Mutational Analysis of MDS and AML Occurring after Treatment for Acute Promyelocytic Leukemia (APL). a Report of 9 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only